Apyx Medical (NASDAQ:APYX) Is In A Good Position To Deliver On Growth Plans

  • In Business
  • 2022-09-29 11:03:42Z
  • By Simply Wall St.

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.

So, the natural question for Apyx Medical (NASDAQ:APYX) shareholders is whether they should be concerned by its rate of cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. First, we'll determine its cash runway by comparing its cash burn with its cash reserves.

View our latest analysis for Apyx Medical

Does Apyx Medical Have A Long Cash Runway?

A company's cash runway is calculated by dividing its cash hoard by its cash burn. As at June 2022, Apyx Medical had cash of US$20m and no debt. Looking at the last year, the company burnt through US$15m. Therefore, from June 2022 it had roughly 16 months of cash runway. That's not too bad, but it's fair to say the end of the cash runway is in sight, unless cash burn reduces drastically. The image below shows how its cash balance has been changing over the last few years.

How Well Is Apyx Medical Growing?

Some investors might find it troubling that Apyx Medical is actually increasing its cash burn, which is up 32% in the last year. The silver lining is that revenue was up 34%, showing the business is growing at the top line. Considering the factors above, the company doesn't fare badly when it comes to assessing how it is changing over time. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

Can Apyx Medical Raise More Cash Easily?

While Apyx Medical seems to be in a fairly good position, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.

Apyx Medical's cash burn of US$15m is about 9.0% of its US$167m market capitalisation. That's a low proportion, so we figure the company would be able to raise more cash to fund growth, with a little dilution, or even to simply borrow some money.

How Risky Is Apyx Medical's Cash Burn Situation?

On this analysis of Apyx Medical's cash burn, we think its revenue growth was reassuring, while its increasing cash burn has us a bit worried. Cash burning companies are always on the riskier side of things, but after considering all of the factors discussed in this short piece, we're not too worried about its rate of cash burn. Taking a deeper dive, we've spotted 3 warning signs for Apyx Medical you should be aware of, and 1 of them shouldn't be ignored.

Of course Apyx Medical may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You'll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here


More Related News

Is Avantium (AMS:AVTX) In A Good Position To Invest In Growth?
Is Avantium (AMS:AVTX) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Calculating The Intrinsic Value Of Bastei Lübbe AG (ETR:BST)
Calculating The Intrinsic Value Of Bastei Lübbe AG (ETR:BST)

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Bastei Lübbe AG...

Is There An Opportunity With ABOUT YOU Holding AG
Is There An Opportunity With ABOUT YOU Holding AG's (FRA:YOU) 48% Undervaluation?

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of ABOUT YOU Holding AG...

Estimating The Fair Value Of PostNL N.V. (AMS:PNL)
Estimating The Fair Value Of PostNL N.V. (AMS:PNL)

How far off is PostNL N.V. ( AMS:PNL ) from its intrinsic value? Using the most recent financial data, we'll take a...

Calculating The Fair Value Of UEM Edgenta Berhad (KLSE:EDGENTA)
Calculating The Fair Value Of UEM Edgenta Berhad (KLSE:EDGENTA)

Today we will run through one way of estimating the intrinsic value of UEM Edgenta Berhad ( KLSE:EDGENTA ) by taking...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply


Top News: Business